← All stocks

Biomarin Pharmaceutical Inc

BMRNPharmaceuticalsLatest filing used: 2026-11-03Filings on SEC EDGAR ↗

Strong balance sheet Fast grower

Fair value per share

No filings-based value

The filings alone are probably missing something here: after debt, the cash earnings in the filings leave nothing for shareholders under this method.

Last close

$57.21

Nov 13, 2026

How we decide

Ten years of results

Revenue

$3.2B in FY2025, up 13% on the year before

FY2016: $1.1BFY2017: $1.3BFY2018: $1.5BFY2019: $1.7BFY2020: $1.9BFY2021: $1.8BFY2022: $2.1BFY2023: $2.4BFY2024: $2.9BFY2025: $3.2B$2B$4BFY16FY19FY22FY25$3.2B
Show as table
YearRevenue
FY2016$1.1B
FY2017$1.3B
FY2018$1.5B
FY2019$1.7B
FY2020$1.9B
FY2021$1.8B
FY2022$2.1B
FY2023$2.4B
FY2024$2.9B
FY2025$3.2B

Cash earnings as a share of sales

26.5% of sales in FY2025

FY2018: -10.1%FY2019: -7.6%FY2020: 1.1%FY2021: -1.2%FY2022: -0.9%FY2023: 6.1%FY2024: 15.8%FY2025: 26.5%-10%10%30%FY16FY19FY22FY2527%
Show as table
YearCash earnings as a share of sales
FY2016–
FY2017–
FY2018-10.1%
FY2019-7.6%
FY20201.1%
FY2021-1.2%
FY2022-0.9%
FY20236.1%
FY202415.8%
FY202526.5%

Shares outstanding

Share count rose 19% over 9 years

FY2016: 166MFY2017: 174MFY2018: 177MFY2019: 179MFY2020: 192MFY2021: 183MFY2022: 189MFY2023: 192MFY2024: 197MFY2025: 197M0100M200MFY16FY19FY22FY25197.4M
Show as table
YearShares outstanding
FY2016166M
FY2017174M
FY2018177M
FY2019179M
FY2020192M
FY2021183M
FY2022189M
FY2023192M
FY2024197M
FY2025197M

No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-11-03. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13.